Literature DB >> 8630584

Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation.

S Chollet-Martin1, C Gatecel, N Kermarrec, M A Gougerot-Pocidalo, D M Payen.   

Abstract

It was recently demonstrated that nitric oxide (NO) inhalation improves arterial oxygenation in patients with the adult respiratory distress syndrome (ARDS). However, the potential adverse reaction of NO on inflammatory cells and mediators in the lung has not yet been investigated. In this study, we evaluated the impact of NO inhalation on lung polymorphonuclear neutrophil (PMN) activation and proinflammatory cytokine release, both of which are involved in the pathophysiology of ARDS. Two groups of patients with ARDS of similar etiologies were compared; one received NO (n=9) and the other did not (n=5). After 4 d of NO inhalation (18 ppm), PMN form bronchoalveolar lavage (BAL) showed a reduction in both spontaneous H2O2 production (p<0.05) and beta 2 integrin CD11b/CD18 expression (p<0.05). Moreover, the high levels of IL8 and IL-6 decreased in BAL fluid supernatants after NO inhalation (p<0.05). In the NO-untreated group of patients with ARDS, neither PMN activation nor levels of IL-8 and IL-6 in BAL fluid changed significantly on Day 4. These results suggest that NO inhalation might reduce lung inflammation in ARDS, as reflected by PMN activation status and IL-8/IL-6 release.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630584     DOI: 10.1164/ajrccm.153.3.8630584

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Safety and efficacy of nitric oxide in chronic lung disease.

Authors:  P L Clark; I I Ekekezie; H A Kaftan; C A Castor; W E Truog
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-01       Impact factor: 5.747

2.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 3.  Therapeutic strategies for severe acute lung injury.

Authors:  Janet V Diaz; Roy Brower; Carolyn S Calfee; Michael A Matthay
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

Review 4.  Acute respiratory distress syndrome in the septic surgical patient.

Authors:  Jose L Balibrea; Javier Arias-Díaz
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

5.  Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome.

Authors:  R Phillip Dellinger; Stephen W Trzeciak; Gerard J Criner; Janice L Zimmerman; Robert W Taylor; Helen Usansky; Joseph Young; Brahm Goldstein
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) prevents lipopolysaccharide (LPS)-induced, sepsis-related severe acute lung injury in mice.

Authors:  Yuki Takaoka; Shigeru Goto; Toshiaki Nakano; Hui-Peng Tseng; Shih-Ming Yang; Seiji Kawamoto; Kazuhisa Ono; Chao-Long Chen
Journal:  Sci Rep       Date:  2014-06-06       Impact factor: 4.379

7.  Inflammatory Mediators in Tracheal Aspirates of Preterm Infants Participating in a Randomized Trial of Inhaled Nitric Oxide.

Authors:  Mandy Laube; Elena Amann; Ulrike Uhlig; Yang Yang; Hans W Fuchs; Michael Zemlin; Jean-Christophe Mercier; Rolf F Maier; Helmut D Hummler; Stefan Uhlig; Ulrich H Thome
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

8.  Toll-like receptor 4/nuclear factor-kappa B pathway is involved in activating microphages by polysaccharides isolated from Fagopyrum esculentum.

Authors:  Zhen Chen; Leilei Yu; Xiaoniao Cai; Fangpeng Ye; Peisheng Jin
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

Review 9.  Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.

Authors:  Fabienne Gebistorf; Oliver Karam; Jørn Wetterslev; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.